

Index

a

absolute quantification (AQUA) 170
 ad hoc software tools 261
 affinity chromatography process
 12–13, 297
 α -1,6-fucosyltransferase (FUT8)
 modulation 198, 229–231
 alpha-spectrum 82
 alternating tangential flow (ATF) 11,
 283, 349, 351
 Amino acid-Polyamine-organocation
 (APC) superfamily 136
 anion exchange chromatography (AEX)
 296
 anNET 141
 5-azacytidine (5-Aza) 107
 5-aza-2'-deoxycytidine (DAC) 107,
 108

b

baby hamster kidney (BHK21) cell lines
 27
 batch culture 10, 35, 105, 261, 264,
 317, 318, 353
 advantage 317
 batch-level analysis 397–398
 B-cell lymphoma 2 (BCL2) gene 74,
 221
 biologically active HCPs 300
 biopharmaceutical cell culture process
 adherent cells 316
 batch culture 317
 fed-batch cultures 317–319
 suspended cells 316

biopharmaceuticals 1, 3, 5, 6, 8, 11–13,
 15–17, 23, 24, 28, 36, 49, 55, 56,
 62, 73, 97, 98, 127–153, 185,
 198–200, 207, 208, 233, 234, 265,
 285, 295, 297, 303, 305, 313–333,
 347, 348, 350–353, 361, 366–370,
 381–383

Biosep device 357–358
 biotherapeutics 172, 227, 279, 280,
 282, 283, 381–382

bisulfite sequencing method 168

c

calcium phosphate-based transient
 transfection 50
 carboxypeptidase D 304
 Cas9 endonuclease 186
 cation exchange chromatography (CEX)
 296
 cell culture process, for TGE 59
 culture longevity-enhancing factors
 59, 60
 q_p -enhancing factors 59
 cell viability on HCP profiles 303
 Cell Xpress™ system 32
 centrifugation 51, 62, 257, 295, 296,
 354, 356
 CentriTech unit 356
 chain termination Sanger sequencing
 method 165
 chemically defined (CD) media
 development, for CHO cells
 basal and feed medium formulations
 283

- cell line development 280
- cell line selection 279–280
- considerations 284
- design of experiment (DoE) approach 280
- fed-batch production process 283, 284
- medium component classification 281
- perfusion process 283
- seed train expansion 281
- standard workflow for 281
- systems and synthetic biology 284–288
- chemically defined feeds 264
- chemically defined media (CDM) 10, 163, 234, 261, 266, 320
- Chinese hamster ovary (CHO) cell line engineering
 - autophagy 225, 226
 - cell division rates and proliferation 226
 - CRISPR/Cas9 system 197, 209
 - CRISPR/Cpf1 system 198
 - CRISPR-mediated targeted integration 199
 - gene knockout 209
 - improving recombinant protein production
 - cellular metabolism 211
 - cellular protein synthesis 218
 - continuous acidification of culture medium 219
 - cytoskeleton dynamics 219
 - miRNAs, potential of 220
 - secretory capacity 218
 - telomeric region of chromosome 8, 219
 - necrosis/necroptosis 225
 - noncoding RNA-mediated gene silencing 209–211
 - overexpression of antiapoptotic genes 221
 - overexpression of engineering genes 208–209
 - posttranslational modifications 227
 - C-terminal amidated species of mAbs 233
 - glycosylation 227, 231
 - N-glycosylation 231
 - O-glycosylation 232
 - sialylation 232, 233
- proapoptotic genes, inhibition of 225
- programmed cell death/apoptosis 221, 222
- sodium butyrate treatment 225
- transcriptomics studies 225
- viral safety 233
- Chinese hamster ovary (CHO) cells
 - chemically defined media development 279
 - epigenomics of 168
 - genetic/genomic instability 97, 99–101
 - genome-scale model 174, 178
 - genome sequencing of 166–167
 - genomic resource development 75
 - glutamine synthetase deficient 73
 - glycomics 172
 - host cell protein risk assessment in 305
 - lipidomics 172
 - low-temperature culture 174
 - metabolomics 171–172
 - microRNAs (miRNA) 167
 - multi-omics profiling
 - bioprocess optimization 174
 - cell line characterization 174–176
 - engineering target identification 176–177
 - proteome database 305
 - proteomics 75–76, 170–171
 - transcriptomics of 75–76, 167
- CHO-K1 cell line 6, 26, 28, 33, 100, 106, 172
- CHO-K1 genome 5, 75, 166, 167
- CHO Protein Predicted Immunogenicity (CHOPPI) 305
- CHO-S cell line 26, 33
- chromatin immunoprecipitation and sequencing (ChIP-seq) 168

- chromatographic method 12, 172
- ¹³C-fluxomics 257, 261, 266
- class 2 type V CRISPR/Cpf1 188
- clonality 9, 36, 73
- ClonePix™ system 9, 32
- co-elution 298
- cofilin-1 219
- computational systems biology 84
- concentrated fed-batch 332
- constraint-based metabolic models 381, 382
- constraint-based modeling approaches 80, 127, 381
- context-specific models (CSMs)
 - ¹³C-labeled flux data 149
 - description 146
 - FAST Consistent Reconstruction 148
 - gene inactivity mediated by metabolism and expression 146
 - integrative metabolic analysis tool 147
 - integrative network inference for tissues method 147–148
 - metabolic adjustment by differential expression 147
 - metabolic context specificity assessed by deterministic reaction evaluation 148
 - model building algorithm 147
 - performance 148–149
 - thresholding value 149
- continuous biomanufacturing 305, 347–362
- continuous cell culture process
 - description 347–348
 - with cell retention (perfusion)
 - advantages 351
 - biomanufacturing facility utilization 352
 - Biosep device 357–358
 - centrifugation 356
 - current status of 360
 - external cell retention device 350
 - filtration based devices 354–355
 - high volumetric productivities 351
 - hydrocyclones 358
 - immobilization/entrapment systems 349–350
 - internal cell retention device 350
 - product quality and consistency 352–353
 - scale up and commercial production 353–354
 - settlers 356–357
 - spin filters 355–356
 - stirred tank bioreactor operation and control 358
 - without cell retention (chemostat) 348
- continuous stirred tank perfusion
 - bioreactor system 358
 - cell bleed/purge 360
 - cell build-up phase 359–360
 - circulation/return pump 359
 - external cell retention device 358
 - feed and harvest flow and volume control 358–359
 - production phase 360
- core fucose 198, 231, 232
- Cre/loxP system 33
- Cricetulus griseus* GEM 129
- CRISPR activation (CRISPRa) 195
- CRISPR/Cas9 system
 - biotechnological potential of 185
 - components 186
 - genome editing
 - experimental design 189–191
 - gene knockout 192–194
 - mechanism of 186–187
 - site-specific gene integration 194–195
 - multiplex genome engineering 192
 - RNA-targeting 196
- CRISPR/Cas13 system 193, 196
- CRISPR/Cas systems
 - engineered Cas9 variants 188
 - evolutionary diversity in bacteria and archaea 187
- CRISPR interference (CRISPRi) 195
- CRISPR RNA (crRNA) 186–188
- critical quality attribute (CQA) 298, 366, 372

- culture media, for transient gene expression 58
 - CycleFreeFlux 143
 - CycleFreeFVA approach 139
 - cytogenetic methods 99, 101
- d**
- dCas9-DNMT3A-DNMT3L fusion protein 112
 - dCas9-p300 fusion construct 110
 - dCpf1-based transcriptional activators 196
 - dead Cas9 (dCas9) 110, 188
 - difficult-to-remove host cell protein (HCP) 298
 - dihydrofolate reductase (DHFR)-deficient CHO sublines 207
 - dimeric cartilage matrix protein-angiopoietin-1 35
 - direct injection-mass spectrometry (DI-MS) 253
 - DNA demethylation 112, 113
 - DNA methylation 102, 107
 - CpG dinucleotides 105
 - global manipulation of 107–108
 - reader proteins of 104
 - targeted DNA methylation 112–113
 - DNA methyltransferases (DNMTs) 54, 102, 112
 - DNA targeting CRISPR/Cas9 system 187
 - DNA transposons 34
 - downstream process development, in therapeutic protein production
 - purification 12–13
 - quality by design (QbD) concept 13–14
 - Drotrecogin alfa 34
 - DXB11 cell line 26
 - dynamic flux balance analysis (DFBA) 375
- e**
- electroporation 7, 8, 30, 51–52, 59–61, 191, 208
 - electroporation-based transfection 51, 52
 - endonuclease-mediated targeted integration method 33
 - energy dissipation rate (EDR) 326
 - engineered Cas9 variants 188
 - epigenetics 101
 - DNA methylation 102
 - histone modifications 102–104
 - long noncoding RNAs 104
 - targeted epigenetic modification 109–113
 - EpiMatrix 305
 - equivalence acceptance criterion (EAC) 399, 400
 - erythropoietin (EPO) 23, 174, 232, 266, 297, 315, 316
 - euchromatin 101, 110
 - extensions 147
- f**
- FAST consistent reconstruction (FASTCORE) 148
 - Fast-SNP 143
 - fed-batch cell culture process
 - development 318, 329
 - bioreactor technologies 331–332
 - near infrared and Raman spectroscopy probes 330
 - perfusion 331, 332
 - fingerprint analysis 253
 - FlexFlux 145
 - Flp/FRT system 15, 33, 199
 - fluorescence-activated cell sorting (FACS) 9, 32, 74, 189
 - flux balance analysis (FBA) 81, 150, 257, 375, 380
 - assumptions 128
 - genome-scale model 129
 - limitations 131
 - biological objective function 133
 - genetic regulation 131
 - kinetics and metabolite concentrations 133
 - limited intracellular space 132
 - thermodynamically infeasible cycles 131

- regulatory networks 145
 - single optimal reaction network state 133
 - flux balance analysis with molecular crowding (FBAwMC) 151
 - flux variability analysis (FVA) 82, 133
 - footprint analysis 253
 - Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer 169
- g**
- gas chromatography–mass spectrometry (GC–MS) 253–256
 - gas entrance velocity 393
 - gene inactivity mediated by metabolism and expression (GIMME)
 - algorithm 146–147
 - gene–protein–reaction (GPR) 77, 130
 - genetic compensation 304
 - genetic/genomic instability, CHO cells 97, 99–101
 - genome editing CRISPR/Cas9-mediated epigenetic modification 196
 - experimental design 189
 - gRNA target site selection and design 189–191
 - plasmid-based delivery 191, 192
 - timeline of 190
 - viral delivery 192
 - gene knockout 192–194
 - mechanism of 187
 - RNA targeting 196
 - site-specific gene integration 194–195
 - transcriptional regulation 195–196
 - genome editing tools, for HCP removal 304
 - genome-scale constraint-based metabolic models 382
 - genome-scale CRISPR screening 197
 - genome-scale metabolic models 76, 82, 127
 - automatic reconstruction methods 77–79
 - draft reconstruction 77
 - external exchange reaction loops 134
 - gene regulation, advantages of 144
 - H⁺-coupled symport transporters 137
 - knowledge-base construction 77
 - mathematical format 79
 - modeling techniques 85
 - Na⁺-linked transporters 136–137
 - omics data 83–84
 - reversible passive antiporters 136
 - reversible passive transporters 135–136
 - validation and evaluation 79–80
 - GIMME by Proteome (GIMMEp) 147
 - glutamine synthetase (GS)-deficient CHO cell lines 207
 - glutathione S transferase- α (GST- α) 302
 - glycoengineering 198
 - glycosylation 1, 5, 8, 12, 23, 24, 34, 35, 38, 54, 76, 85, 102, 172, 174, 197, 198, 225, 227–229, 231, 232, 265, 266, 280, 282, 284, 305, 314–315, 319, 320, 322, 325–329, 332, 369, 375–378, 382
 - pathways 231
 - guide RNA (gRNA) 33, 110, 186
 - target site selection and design 189, 191
- H**
- H⁺-coupled symport transporters 137
 - Henderson–Hasselbalch equation 325, 326
 - high throughput omics technologies
 - mass spectrometry 168–170
 - sequencing-based 165–168
 - histone acetylation 59, 107–109
 - homology-directed repair (HDR) 15, 34, 187, 194
 - homology-independent targeted integration (HITI) method 195
 - host cell proteins (HCPs)
 - detection and monitoring methods 300–302

- host cell proteins (HCPs) (*contd.*)
- enzyme-linked immunosorbent assay 300–302
 - immunoassays 300, 302, 306
 - impurity removal process
 - antibody product 296–297
 - depth filtration step 296
 - difficult-to-remove HCPs 298
 - harvested cell culture fluid 296
 - hydrophobic interaction
 - chromatography 296
 - ion exchange chromatography 296
 - non-antibody protein product 297
 - protein A chromatography 296
 - non-gel based proteomics approaches 302
 - on polysorbate degradation 233
 - removal/control of 303
 - downstream strategies 304
 - upstream process 303
 - residual 298–300
 - risk assessment in CHO cells 305
 - sodium dodecyl
 - sulfate-polyacrylamide gel electrophoresis 302
 - 2D-differential in-gel electrophoresis 302
- human embryonic kidney (HEK293) cells 5, 24, 35, 49
- human tissue plasminogen activator 1, 49, 73, 211
- hybrid perfusion/fed-batch process 16
- hydrocyclones 358
- hydrophobic interaction
 - chromatography (HIC) 296
- I**
- Illumina sequencing 76, 166, 167
- immunoassays 300, 302, 306
- immunoglobulin G (IgG) sepharose
 - affinity chromatography 297
- insect cells 23, 24
- insulin 23, 60, 218, 297, 319
- integrative metabolic analysis tool (iMAT) 147
- integrative network inference for tissues (INIT) method 147–148
- interleukins (ILs) 297
- internal ribosome entry sites (IRES) 7, 74
- International Council for Harmonisation (ICH) quality guideline 295, 391
- ion exchange chromatography (IEX) 296
- ionizers 168
- isobaric tags for relative and absolute quantitation (iTRAQ) 170, 302
- J**
- large-scale TGE-based protein production 55, 60–62
- lectin-based microarrays 172
- linear ion trap (LIT) 169
- lipofection 7, 8, 52, 112, 208
- liposome-based transfection reagents 52, 53
- liposome-based transient transfection 52–53
- liquid chromatography–mass spectrometry (LC–MS) 253–256
- liquid chromatography–tandem mass spectrometry (LC–MS/MS) 302
- Il-COBRA 143
- long noncoding RNAs (lncRNAs) 104
- loop law 139
- m**
- macromolecular crowding 132, 150
- major facilitator superfamily (MFS) 135–136
- mammalian cell culture process
 - development
 - aggregation 316
 - ammonium accumulation 322
 - basal media 319–320
 - batch cultures 10, 317
 - cell culture supplements 327–329
 - charge heterogeneity 315–316
 - culture environment optimization 10
 - fed-batch cultures 11, 317–319
 - feed media 321
 - design 323–325

- glycosylation 314–315, 328–329
- lactate accumulation 322
- media development 10
- metabolite based feeding strategy 321–322
- objectives of 314–316
- osmolality 322
- perfusion culture 11
- pH-dependent feeding strategy 322
- process variable design 325–327
 - culture duration 327
 - dissolved oxygen 326–327
 - pH and pCO₂ 325–326
 - temperature 325
- product quality 314
- quality analysis 12
- respiration based feeding strategy 323
- scale up process 11, 12
- single use bioreactor systems 11–12
- yield 314, 328
- mammalian cell cultures 1, 3, 10, 11, 13, 58, 60, 73, 84, 252, 257, 313, 319, 325, 326, 332, 333, 367–371, 374, 377
- mammalian host cell lines 3, 5, 24–27, 54
- mass analyzers 168, 169
- mass conservation constraints 140
- mass spectrometry (MS) 38, 76, 164, 168–170, 252, 255, 256, 259, 285, 302, 324, 368
- mass spectrometry-based omics technologies
 - CHO cells
 - glycomics 172
 - lipidomics 172
 - metabolomics 171–172
 - proteomics 170–171
 - liquid chromatography–mass spectrometry 169
 - mass spectrometer, components of 168
 - tandem mass spectrometry 169
- matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF-MS) 368, 369
- matrix attachment regions (MARs) 7, 74, 107
- mechanistic-based kinetic models 382
- mechanistic mathematical models 84
- metabolic adjustment by differential expression (MADE) 147
- metabolic context-specificity assessed by deterministic reaction evaluation (mCADRE) 148
- metabolic data, in mammalian bioprocessing 261
 - clonally derived recombinant cell lines 263
 - genetic engineering 265–266
 - glycosylation profiles 265
 - growth phase vs. metabolism 261–263
 - improving biomass and recombinant protein yield 263–265
 - lactate shift 263
 - metabolic indicators of high productivity 263
 - UDP-Gal precursor 265
- metabolic engineering of cell lines 85
- metabolic flux 80, 151, 257, 281, 287, 369, 375, 378
- metabolic modeling with enzyme kinetics (MOMENT) 151
- metabolite-based feeding strategy 321–322
- metabolite profile generation 253
 - mass spectrometry 255–256
 - nuclear magnetic resonance 254–255
- metabolite profiling 251–267
- metabolites 74, 76–83, 86, 127–131, 133–138, 140, 141, 144–146, 148, 149, 151–153, 171, 172, 178, 221, 251–267, 280, 281, 283, 285–287, 295, 321–324, 330, 331, 359, 366, 378–380, 382, 396
 - detection and quantitation 252
- metabolite sample preparation
 - extracellular 257
 - extraction methodology 257
 - metabolic flux analysis 257

- metabolite sample preparation (*contd.*)
 - quenching of intracellular samples 257
 - sampling 256
 - metabolome 128, 174, 176, 251–253, 258
 - metabolomics 251, 253
 - data analysis 257–260
 - data interpretation and integration 260–261
 - data mining techniques 258, 260
 - data processing 258
 - univariate and multivariate methods 258
 - methylation-induced transcriptional silencing 37
 - microbial systems 23, 24, 381
 - microhomology-mediated end joining (MMEJ) 34, 187
 - microRNAs (miRNAs) 104, 167, 210, 211, 227
 - potential of 220
 - miR-143 217, 221
 - miR-2861 216, 220
 - miR-30 family, in CHO cells 220
 - miR-34a 217, 220, 227
 - miR-466h 227
 - miR-483 217, 221
 - mixed-integer linear programming (MILP) algorithm 82
 - mixed-mode chromatography 12, 303, 304
 - model building algorithm (MBA) 147
 - model extraction methods (MEMs) 83
 - molecular crowding 132, 150–152
 - monoclonal antibodies (mAbs) 5, 23, 60, 61, 74, 198, 208, 212, 215, 225, 230, 231, 233, 234, 266, 279–281, 295, 313, 314, 347, 360, 361, 378–380
 - multilocus genomic fingerprinting 99
 - multiomic approaches 14
 - multi-omics data integration 177
 - network-based modeling approaches 178
 - statistical methods 177
 - multiple reaction monitoring (MRM) 302
 - murine NS0 cell 3, 27, 108
 - multicolor fluorescence in situ hybridization (mFISH) 100
- N**
- Na⁺ linked transporters 136–137
 - network-embedded thermodynamic analysis (NET) 140
 - NExT 140
 - next-generation RNA sequencing technology 211
 - next-generation sequencing (NGS) 100, 127, 189, 285
 - nickase Cas9 (nCas9) 188
 - N-linked glycosylation 24, 229, 231, 232, 314, 315
 - nonchromatographic separation 12, 13
 - noncoding RNA mediated gene silencing 209–211
 - non-homologous end joining (NHEJ) 15, 187
 - non-viral-based gene delivery 50–53
 - nonviral gene transfer 7, 30
 - nuclear magnetic resonance (NMR) 127, 171, 253–256, 285, 324, 365
 - nucleosomes 101–104, 144, 196
 - nucleotide sequencing techniques, historical development of 165–166
- O**
- O-linked glycosylation 314, 315
 - omics data 15, 83–84, 127, 146, 148, 164, 165, 172–174, 176–178, 200, 252, 261, 286, 382
 - Orbitrap 169
 - oxygen transfer coefficient 323, 392–393, 401
 - oxygen transfer rate (OTR) 393–395
 - oxygen uptake rate (OUR) 323
- p**
- parsimonious flux balance analysis (pFBA) 131, 143, 148, 149, 152

- PAT-A framework 365
- perfusion culture
- advantages 351
 - Biosep device 357–358
 - centrifugation 356
 - external cell retention device 350
 - filtration based devices 354–355
 - hydrocyclones 358
 - immobilization/entrapment systems 349–350
 - internal cell retention device 350
 - settlers 356–357
 - spin filters 355–356
- phase partitioning method 13
- pH-dependent feeding strategy 322
- PiggyBac transposon 34
- piwi-interfering RNAs (piRNAs) 104
- plant cells 23, 24
- platform technology development 3, 14–16
- polyclonal antibodies 300
- polyclonal anti-HCP antibody 300
- polyethylenimine (PEI)-based transient transfection 52
- post-transcriptional gene silencing (PTGS) 104
- power/volume (P/V) ratio 392, 401
- process analytical technology (PAT)
- advanced analytical methods 369
 - amino acid supplementation 375–377
 - challenges 365–366
 - chemometric techniques 369
 - data analysis and modeling tools 369–370
 - definition 365
 - design space (DS) exploration strategy 372
 - fluorescence spectroscopy 368
 - high performance liquid chromatography 366
 - mAb glycosylation 378
 - mammalian cell culture raw material characterization 374–375
 - mid-infrared (MIR) spectroscopy 367
 - multiwavelength UV spectroscopy 372–374
 - NIR spectroscopy 367
 - nutrient consumption metabolism 378
 - protein mixture quantification 372–374
 - quantitative intracellular flux modeling 381–382
 - Raman spectroscopy 367–368
 - raw material performance, in mammalian cell culture 370–371
 - process-related impurities 12, 295, 353
 - product-related impurities 12, 295
 - protein-A method 13
 - protein-based drugs 85
 - protein folding 1, 5, 109, 200, 316, 325
 - protein therapeutics 85, 279–288
 - proteomics approach, for HCP detection 302
 - pyrosequencing-based method 165
- q**
- quadrupole analyzer 169
- quadrupole ion trap (QIT) 169
- quality by design (QbD)
- advanced analytical methods 369
 - amino acid supplementation 375–377
 - challenges 365–366
 - chemometric techniques 369
 - data analysis and modeling tools 369–370
 - design space exploration strategy 372
 - fluorescence spectroscopy 368
 - high-performance liquid chromatography 366
 - mAb glycosylation 378
 - mammalian cell culture raw material characterization 374–375
 - mid-infrared spectroscopy 367
 - multiwavelength UV spectroscopy 372–374
 - NIR spectroscopy 367

- quality by design (QbD) (*contd.*)
 - nutrient consumption metabolism 378
 - protein mixture quantification 372–374
 - quantitative intracellular flux modeling 381–382
 - Raman spectroscopy 367–368
 - raw material performance, in mammalian cell culture 370–371
- quantification concatamers (QconCAT) 170
- r**
- reader proteins, of DNA methylation 104
- recombinant cell line development, for therapeutic protein production
 - CHO cells
 - clone selection 31–32
 - dihydrofolate reductase (DHFR) system 28
 - gene amplification 30–31
 - glutamine synthetase (GS) system 28
 - selection medium 30
 - site-specific integration 32
 - stable expression system 27
 - transfection methods 30
 - transient expression system 27
 - vector construction 29–30
 - clonality 36
 - clone selection 8–9
 - expression vector 7
 - host selection 6
 - necessity for 34–35
 - quality 37–38
 - stability 36–37
 - transfection/selection 7
- recombinant protein expression 176, 211, 220, 251, 263
- recombinase-mediated cassette exchange (RMCE) 15, 33, 194, 199
- reconstructed mammalian GEMs 129
- regulatory flux balance analysis (rFBA) 145
- regulatory steady-state analysis (RSA) 145
- residual host cell proteins (HCPs)
 - biological activity 299–300
 - drug efficacy 298–299
 - immunogenicity 299
 - quality and shelf life 298–299
- resource balance analysis (RBA) 151
- respiration based feeding strategy 323
- RNA-induced silencing complex (RISC) 210
- RNA interference (RNAi) 15, 197, 209
- RNA sequencing (RNA-seq) 144, 165, 166, 195, 199, 211
- s**
- Saccharomyces cerevisiae* iLN800 model 131
- scale down model (SDM)
 - development challenges 391
 - equivalence testing 399–401
 - evaluation 395–401
 - batch-level analysis 397
 - multivariate analysis 396–399
 - observation level analysis 397
 - qualification data set 396–397
 - scores contribution plots 398–399
 - univariate analysis 395–396
 - gas entrance velocity 393
 - oxygen transfer coefficient 392–393
 - oxygen transfer rate 393–395
 - power/volume ratio and air velocity 392
 - refinement workflow 395
 - scores contribution plots 398–399
- secretory capacity, of CHO cells 218
- selected reaction monitoring (SRM) 171
- semicontinuous cultures 348, 351
- semisolid matrix-based systems 9
- sequential quadratic programming (SQP) method 140

- sequential window acquisition of
 - theoretical mass spectra (SWATH) MS 171, 176
 - single-cell cloning process 36, 74, 209
 - single molecule real-time sequencing technology (SMRT) 166
 - single-stranded oligodeoxynucleotides (ssODNs) 194
 - small-interfering RNAs (siRNAs) 104, 209, 210
 - sodium butyrate (NaBu) 59, 74, 108, 109, 225, 328
 - Sp2/0-Ag14 cell lines 24, 27
 - SpCas9-mediated DNA recognition 187
 - spin filters 355–356
 - stable human cell line development process 16, 35–36
 - stable isotope labeling with amino acids (SILAC) 170
 - stoichiometric models 128, 138, 140, 142, 382
 - SV40-based episomal replication system 54
 - synthetic biology 114, 284–288, 333
 - systems biology 15, 84, 86, 284–288, 375
- T**
- TALE-Sin3a fusion constructs 111
 - tangential flow filtration cell retention device 283, 355
 - targeted integration (TI)-based CLD 15
 - targeted integration method 32, 33
 - targeted metabolomics approach 253
 - therapeutic protein production, in
 - mammalian cells 5
 - baby hamster kidney (BHK21) cell lines 27
 - CHO cell lines 25–26
 - downstream process development 12–14
 - HEK293 cell lines 26
 - HKB-11 cell lines 26
 - improving specific productivity 5
 - increasing cell mass 5
 - murine NS0 cell lines 27
 - PER.C6 cell lines 26
 - protein quality 5
 - purification 12–13
 - quality by design (QbD) 13–14
 - recombinant cell line development guidelines 6–9
 - Sp2/0-Ag14 cell lines 27
 - therapeutic proteins 347
 - description 1
 - global market value 1
 - mammalian manufacturing platform 1
 - quality of 37–38
 - thermodynamic variability analysis (TVA) 141
 - thermodynamically infeasible cycles 131, 134
 - algorithms developed 138–139
 - exclusion of
 - minimization of total flux 142–144
 - thermodynamic constraints 140
 - manual curation 139–140
 - Monte Carlo method 139
 - transporter types 135
 - visualizing flux on network maps 138
 - Wright and Wagner (WW) algorithm 138
 - thermodynamics-based metabolic flux analysis (TMFA) 141
 - time-of-flight (TOF) mass analyzer 169, 255
 - titer 3, 8, 9, 11, 31, 35, 49, 50, 54, 56–61, 73, 74, 85, 107, 163, 211–216, 218, 220, 222–225, 265, 266, 280, 318, 320, 322, 325, 327–330, 332, 333, 348, 351, 352, 360–362, 375–377
 - trans-activating crRNA (tracrRNA) 186
 - transcription activator-like effector nuclease (TALEN) 33, 197, 209, 304
 - transcription activator-like effectors (TALEs) 33, 110

- transforming growth factor β 1 (TGF β 1) 300
 - transient gene expression (TGE)-based protein production
 - cell culture strategies 58–60
 - CHO cells 56–58
 - coexpression strategies 54
 - episomal replication 53–54
 - expression vector composition and preparation 53
 - HEK293 cells 55–56
 - HKB-11 cells 58
 - large-scale 60–62
 - non-viral-based gene delivery 50
 - viral-based gene delivery 50
 - transposon-mediated gene integration method 34
 - 2D gel electrophoresis 76
- u**
- ubiquitous chromatin opening element (UCOE) 107
- untargeted metabolomics approach 253
- uridine diphosphate
 - N*-acetylglucosamine (UDP-GlcNAc) 328
- v**
- valeric acid 109, 328
 - valproic acid 59, 109
 - Van't Riet equation 392
 - viral-based gene delivery 50
 - viral promoters 53, 105
 - virus-mediated transfection method 30
- W**
- Warburg effect 150, 151
- Z**
- zinc-finger nuclease (ZFN) 33, 197, 209, 266
 - zinc finger proteins (ZFP) 110, 212